Leveraging cDC1 biology and function for enhanced immunotherapy

Journal of Experimental Medicine · Published 2026-05-15 · DOI 10.1084/jem.20241199

Authors (4)

Ross W. Ward, Uddipan Kar, Sreekumar Balan, Nina Bhardwaj

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Ward, R., Kar, U., Balan, S., et al. (2026). Leveraging cDC1 biology and function for enhanced immunotherapy. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20241199

Related articles

• Aquaporin-1 sustains lymphangiogenic responses in hyperosmotic inflammatory microenvironments · Journal of Experimental Medicine · 2026 · Same journal
• CNOT3 supports ILC2 differentiation and function by destabilizing Tbx21 and Rorc transcripts · Journal of Experimental Medicine · 2026 · Same journal
• Flawed translation triggers oncogenic B–T cell communication · Journal of Experimental Medicine · 2026 · Same journal
• Identification of secondary microglial formation centers in the human fetal brain · Journal of Experimental Medicine · 2026 · Same journal
• eIF3e-mediated translational checkpoint maintains immune tolerance and prevents lymphoid malignancy · Journal of Experimental Medicine · 2026 · Same journal
• Decoding TCR specificity and T cell fate at the immunological synapse · Journal of Experimental Medicine · 2026 · Same journal
• UBE2F impedes CD8 T cell memory · Journal of Experimental Medicine · 2026 · Same journal
• Chimeric allergen receptor regulatory T cells suppress birch pollen allergic airway inflammation · Journal of Experimental Medicine · 2026 · Same journal
• Complement-regulated homeostatic proliferation controls memory B cell longevity and repertoire composition · Journal of Experimental Medicine · 2026 · Same journal
• BACH2 controls ILC3 function via PPARγ-dependent mitochondrial metabolism · Journal of Experimental Medicine · 2026 · Same journal